NYSE$AGL

agilon health inc. · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Reported strong Q3 2023 results with revenue increasing 75% and Medicare Advantage membership increasing 58%.

agilon health reported a strong third quarter with significant growth in revenue and Medicare Advantage membership. The company's decision to sell MDX Hawaii will allow it to focus on its core partner markets. Total revenue increased by 75% to $1.22 billion, and Medicare Advantage membership increased by 58% to 420,300.

  • Total members live on the agilon platform increased to 508,000 as of September 30, 2023, including 420,300 Medicare Advantage members and 87,700 ACO REACH beneficiaries.
  • Total revenue of $1.22 billion increased 75% during the third quarter 2023, compared to $695 million in the third quarter 2022.
  • Gross profit of $30 million in the third quarter 2023, compared to $26 million in the third quarter 2022.
  • Medical margin of $108 million increased 42% during the third quarter 2023, compared to $76 million in the third quarter 2022.

Headline financials

Total Revenue

$1.22B

Previous: $695M+75.0%
EPS (adj)

-$0.08

Previous: -$0.07-14.3%
Medicare Advantage Members

420.3K

Previous: 266.6K+57.7%
Total Members

508.0K

No prior period
Avg. MA Members

425.1K

Previous: 270.1K+57.4%
Capital Expenditures

-$11.9M

Previous: -$11.9M+0.3%
Free Cash Flow

-$43.3M

Previous: -$42.6M-1.7%
Net Income

-$31.4M

Previous: -$30.7M-2.5%
Operating Income

-$49M

Previous: -$29.5M-65.9%
Gross Profit

$30.5M

No prior period
Cash & Equivalents

$168M

Previous: $551M-69.5%
Total Assets

$2.28B

Previous: $1.87B+21.8%

Revenue & EPS history

agilon health · Revenue · Quarterly

$1.22B

Q3 2023+75%vs Q3 2022
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Revenue by segment

agilon health · $1.15B total across 2 segments · Q2 2023

  • Medical Services Revenue
    $1.15B+71.4%
  • Other Operating Revenue
    $2.01M+111.4%

Forward guidance

Agilon health provided outlook for Q4 2023, excluding MDX Hawaii. They expect total revenues between $1,050 million and $1,060 million, medical margin between $55 million and $70 million, and Adjusted EBITDA between -$36 million and -$24 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-2.6%

Avg return

Earnings day

-0.0%

Avg return

5 days after

+6.7%

Avg return

30 days after

50%

10 / 20 earnings

Positive

+20.2%

Q4 2025

Best reaction

-36.1%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.2%+122.0%+256.9%
Q4 2025+20.2%+13.4%-20.8%
Q3 2025+5.1%-9.0%-9.9%
Q1 2025-25.6%-33.4%-51.6%
Q4 2024-7.4%-17.9%+23.7%
Q3 2024-36.1%-35.1%-24.7%
Q2 2024-12.7%-14.6%-36.8%
Q1 2024+7.5%+7.5%+40.8%
Q4 2023+3.1%-2.1%-1.1%
Q3 2023-13.1%-19.0%-33.1%
Q2 2023+0.7%+3.7%-7.9%
Q1 2023-3.4%-6.6%-18.9%
Q4 2022+15.4%+14.8%+12.0%
Q3 2022-12.7%-7.9%-8.6%
Q2 2022-3.3%-0.4%-20.3%
Q1 2022-8.6%-19.4%+1.3%
Q4 2021+10.6%+2.4%+31.7%
Q3 2021+2.7%+3.6%-9.5%
Q2 2021-3.8%-6.3%-3.4%
Q1 2021+6.3%+4.0%+14.0%
Q4 2020
Q3 2020
Q2 2020
Q1 2020
Q4 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro